These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 6289732)

  • 1. Inconsistency of synergy between the beta-lactamase inhibitor CP-45,899 and beta-lactam antibiotics against multiply drug-resistant Enterobacteriaceae and pseudomonas species.
    Fass RJ
    Antimicrob Agents Chemother; 1981 Feb; 19(2):361-3. PubMed ID: 6289732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variation in the potentiation of beta-lactam antibiotic activity by clavulanic acid and sulbactam against multiply antibiotic-resistant bacteria.
    Aldridge KE; Sanders CV; Marier RL
    J Antimicrob Chemother; 1986 Apr; 17(4):463-9. PubMed ID: 3011724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic activity of piperacillin in combination with beta-lactamase inhibitors.
    Neu HC; Fu KP
    Antimicrob Agents Chemother; 1980 Oct; 18(4):582-5. PubMed ID: 6255862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pO2 and pH on synergy of tazobactam and beta-lactam antibiotics against beta-lactamase producing Enterobacteriaceae.
    König C; Blaser J
    J Antimicrob Chemother; 1995 Sep; 36(3):513-9. PubMed ID: 8830015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A sulfone beta-lactam compound which acts as a beta-lactamase inhibitor.
    Aswapokee N; Neu HC
    J Antibiot (Tokyo); 1978 Dec; 31(12):1238-44. PubMed ID: 310815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads.
    Jacobs MR; Aronoff SC; Johenning S; Yamabe S
    J Antimicrob Chemother; 1986 Aug; 18(2):177-84. PubMed ID: 3019984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of beta-lactamase inhibitors in combination with new beta-lactam antibiotics against resistant gram-negative organisms.
    Bolivar R; Weaver SS; Bodey GP
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3):255-60. PubMed ID: 6086213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.
    Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S
    Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes.
    Appelbaum PC; Jacobs MR; Spangler SK; Yamabe S
    Antimicrob Agents Chemother; 1986 Nov; 30(5):789-91. PubMed ID: 3026241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 6 beta-Iodopenicillanic acid (UI-38,006), a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactam compounds: initial bacteriological characterization.
    Moore BA; Brammer KW
    Antimicrob Agents Chemother; 1981 Sep; 20(3):327-31. PubMed ID: 6272628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bactericidal activity of cefoperazone with CP-45,899 against large inocula of beta-lactamase-producing Haemophilus influenzae.
    Yu PK; Washington JA
    Antimicrob Agents Chemother; 1981 Jul; 20(1):63-5. PubMed ID: 6269484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides.
    Retsema JA; English AR; Girard AE
    Antimicrob Agents Chemother; 1980 Apr; 17(4):615-22. PubMed ID: 6249192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of combinations of beta-lactam antibiotics with beta-lactamase inhibitors against cephalosporinase-producing bacteria.
    Kitzis MD; Ferré B; Coutrot A; Acar JF; Gutmann L
    Eur J Clin Microbiol Infect Dis; 1989 Sep; 8(9):783-8. PubMed ID: 2556277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Lactamase Inhibitors Enhance the Synergy between β-Lactam Antibiotics and Daptomycin against Methicillin-Resistant Staphylococcus aureus.
    Henson KE; Yim J; Smith JR; Sakoulas G; Rybak MJ
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-resistance to beta-lactam-beta-lactamase inhibitor combinations and clindamycin among cefoxitin-resistant and cefoxitin-susceptible strains of the Bacteroides fragilis group.
    Aldridge KE
    Diagn Microbiol Infect Dis; 1993 Oct; 17(3):251-6. PubMed ID: 8112038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins.
    Wise R; Andrews JM; Bedford KA
    J Antimicrob Chemother; 1980 Mar; 6(2):197-206. PubMed ID: 6247316
    [No Abstract]   [Full Text] [Related]  

  • 17. In-vitro activity of five beta-lactam/beta-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosa.
    McLaughlin JC; Barry AL; Fuchs PC; Gerlach EH; Hardy DJ; Pfaller MA
    J Antimicrob Chemother; 1994 Feb; 33(2):223-30. PubMed ID: 8182003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of YTR 830.
    Jacobs MR; Aronoff SC; Appelbaum PC; Yamabe S
    J Chemother; 1989 Jun; 1(3):151-4. PubMed ID: 2552029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-disk synergy test positivity in Stenotrophomonas maltophilia clinical strains.
    Hejnar P; Kolár M; Chmela Z
    Folia Microbiol (Praha); 2004; 49(1):71-4. PubMed ID: 15114869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
    Stratton CW; Weeks LS; Aldridge KE
    Diagn Microbiol Infect Dis; 1992; 15(4):321-30. PubMed ID: 1611847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.